Aims: The Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma.
Methods: With representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting's process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries. Supported by major orthopaedic oncology organizations, the meeting used a modified Delphi process to develop consensus statements through online questionnaires, thematic groupings, narrative reviews, and anonymous pre-meeting polling.
Results: Strong (> 80%) consensus was achieved on 19 out of 21 statements, reflecting agreement among delegates. Key areas of consensus included the role of radiology in diagnosis and surveillance, the management of locally recurrent disease, and the treatment of dedifferentiated chondrosarcoma. Notably, there was agreement that routine chemotherapy has no role in chondrosarcoma treatment, and radiological surveillance is safe for intraosseous chondrosarcomas. Despite the overall consensus, areas of controversy remain, particularly regarding the treatment of atypical cartilage tumours and surgical margins. These unresolved issues underscore the need for further research and collaboration within the orthopaedic oncology community.
Conclusion: BOOM represents the largest global consensus meeting in orthopaedic oncology, providing valuable guidance for clinicians managing chondrosarcoma worldwide. The consensus statements offer a reference for clinical practice, highlight key research priorities, and aim to improve patient outcomes on a global scale.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1302/0301-620X.107B2.BJJ-2024-0643.R1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and functional characterization of T-cell exhaustion-associated lncRNA AL031775.1 in osteosarcoma: a novel therapeutic target.
Front Immunol
March 2025
Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Background: Osteosarcoma, an aggressive bone malignancy predominantly affecting children and adolescents, presents significant therapeutic challenges with a 5-year survival rate below 30% in metastatic cases. T-cell exhaustion, characterized by the overexpression of immune checkpoint molecules, contributes to osteosarcoma progression and immune evasion. Although targeting these inhibitory pathways has shown potential in restoring T-cell activity, the molecular regulators of T-cell depletion in osteosarcoma are poorly understood.
View Article and Find Full Text PDFMetastatic olfactory neuroblastoma with unusual solitary metastasis to femur: a case report and literature review.
World J Surg Oncol
March 2025
Department of Orthopedic Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Background: Olfactory neuroblastoma (ONB) is a rare malignancy that develops in the nasal cavity, with appendicular skeletal metastases being exceptionally uncommon. We report the case of a middle-aged male with ONB, presenting with an unusual biopsy-confirmed solitary metastasis to the left proximal femur.
Case Presentation: A 33-year-old male was previously diagnosed with olfactory neuroblastoma in the skull base after initial clinical presentation with progressive left-sided nasal obstruction for six months.
Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice.
Nat Commun
March 2025
Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Overcoming immunosuppression in the tumor microenvironment (TME) is crucial for developing novel cancer immunotherapies. Here, we report that IL-16 administration enhances the polarization of T helper 1 (Th1) cells by inhibiting glutamine catabolism through the downregulation of glutaminase in CD4 T cells and increases the production of Th1 effector cytokine IFN-γ, thus improving anti-tumor immune responses. Moreover, we find that establishing an IL-16-dependent, Th1-dominant TME relies on mast cell-produced histamine and results in the increased expression of the CXCR3 ligands in tumor-associated macrophages (TAM), thereby improving the therapeutic effectiveness of immune checkpoint blockade (ICB).
View Article and Find Full Text PDFRetrospective nationwide survey of pediatric RDD in Japan: a high prevalence of mutations in the kinase pathway genes.
Int J Hematol
March 2025
Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Background: Rosai-Dorfman-Destombes disease (RDD) is a rare form of histiocytosis, characterized by the accumulation of S100 protein-positive and CD1a-negative histiocytes with emperipolesis. Recently, oncogenic mutations in mitogen-activated protein kinase pathway genes were reported in nearly half of RDD patients.
Methods: We conducted a nationwide retrospective survey of childhood RDD in Japan.
Indications and clinical outcomes in patients with soft-tissue sarcoma attached to the bone receiving tumorendoprosthetic replacement after tumor resection.
Arch Orthop Trauma Surg
March 2025
Department of Orthopedic Oncology, Universitätsklinikum Essen (AöR), Hufelandstraße 55, 45147, Essen, Germany.
Introduction: Bone resection followed by endoprosthetic reconstruction (EPR) in the treatment of soft tissue sarcoma (STS) is rare and associated with unique challenges. This study aimed to analyze the indications, results and factors affecting the results of these cases.
Materials And Methods: Twelve patients (7 men and 5 women, median age 49 years) who underwent resection and endoprosthetic reconstruction due to soft tissue sarcoma of the extremity between 2010 and 2021 were analyzed retrospectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!